Solventum Named Top Med-Tech Pick by BTIG on Strategic Separation Plans

BTIG has identified Solventum Corporation (NYSE:SOLV) as its top pick in the medical technology sector, maintaining a Buy rating and a $95 price target on the company's stock. The investment firm's positive outlook follows recent meetings with Solventum's senior management, including CEO Bryan Hanson and CFO Wayde McMillan.

Analyst Rationale

According to BTIG, Solventum is well-positioned for growth driven by operational improvements and key strategic initiatives. The firm's analysis points to the planned separation of the company's Health Information Systems (HIS) division as a significant potential catalyst for unlocking shareholder value.

BTIG's valuation model projects a strong growth trajectory for Solventum through fiscal year 2028, with key estimates including:

• An annual top-line growth rate of approximately 4%.
• A 9% compound annual growth rate (CAGR) in adjusted earnings per share.
• A core business organic growth target of 4% to 5%, which is expected to remain intact regardless of the HIS separation outcome.

The firm's $95 price target is based on a 12.5x price-to-earnings multiple, which BTIG considers fair given the company's growth profile. Analysts also highlighted significant market penetration opportunities for Solventum's MedSurg division, particularly in infection prevention and negative pressure wound therapy.

Ad

Focus on HIS Division Separation

Solventum's management is moving forward with the separation of its HIS business, a process expected to take 12 to 18 months. The company has indicated the final method of separation will be determined by the option that best maximizes shareholder value, weighing factors like cash proceeds and execution certainty.

BTIG noted that while broader market uncertainty around artificial intelligence has compressed multiples for healthcare IT companies, strategic buyers are likely to value Solventum's HIS unit at a premium. This is attributed to its dominant position, holding an estimated 80% market share in revenue cycle management. Furthermore, the company's free cash flow is expected to improve significantly in the fourth quarter of 2026 as costs related to the separation begin to roll off.

Recent Performance

BTIG's confidence is supported by Solventum's recent financial results. The company reported second-quarter profit and sales that surpassed analyst estimates, with adjusted earnings of $2.55 per share on revenue of $2.2 billion. Following the strong performance, which was driven by solid organic growth, Solventum also raised its financial outlook for the year.